Dose-dependent decreases in targeted fatty acids were seen with YTX-7739, an investigational therapy for Parkinson’s disease, suggesting the medicine engages its therapeutic target, according to the results of a Phase 1a multiple-ascending dose study in healthy volunteers. YTX-7739 is a...
美国波士顿马萨诸塞州总医院的Christian E. Badr等通过对GSC细胞株和GBM荷瘤小鼠模型的研究,明确SCD抑制剂YTX-7739靶向DNLS诱导脂质毒性和抑制DNA损伤修复,发挥对GBM的治疗效果;结果发表于2023年1月的《Science Translational Medicine》在线。 ——摘自文章章节 ...
YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SC...
Yumanity Therapeutics recently reported its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled Phase 1b clinical trial in patients with mild-to-modera...
中文名称: 中文同义词: 英文名称:YTX-7739 英文同义词:YTX-7739 CAS号: 分子式: 分子量:0 EINECS号: 信息错误报告 您的Email: 按国家浏览YTX-7739国外供应商中国供应商 YTX-7739推荐供应商 建议您优先选择企业会员,我们对企业会员产品有严格审核。 1